Eugene Shenderov, PhD
Medical Oncology · Baltimore, MDNPI 1720358633
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $852 of the $1,170 with a category attached, or 72.8%. 5 manufacturers reported payments, led by Sanofi at 34.3% of the total. Reporting peaked in 2019 at $402 and has fallen 89.2% since, to $43 in 2025. That places this record below the midpoint for medical oncology clinicians in MD, where the typical reported total is $4,199.
Across 14 payments — averaging $83.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$402
- Macrogenics, Inc.$220
- AVEO Pharmaceuticals, Inc.$210
- Exelixis Inc.$174
- AstraZeneca$165
Across 100 payments — averaging $25,458 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$1.2M
- Macrogenics, Inc.$1.1M
- Merck$231K
What the payments were for
- Travel & lodging$27523%
- Food & beverage$85273%
- Education$434%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 6 | $402 |
| Macrogenics, Inc. | 3 | $220 |
| AVEO Pharmaceuticals, Inc. | 1 | $210 |
| Exelixis Inc. | 1 | $174 |
| AstraZeneca | 3 | $165 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NO PRODUCT DISCUSSED$287
- FOTIVDA$210
- Cabometyx$174
- LYNPARZA$104
How this compares
$1,170 in reported general payments places this provider in the 40th percentile of 180 medical oncology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NubeqaDarolutamide | 48 | $644,683 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Baltimore
- Mario EisenbergerBaltimore$2.9M
- David SidranskyBaltimore$520K
- Carole MillerBaltimore$331K
- Mark LevisBaltimore$323K
- Tanguy Lim-SeiwertBaltimore$301K
- Shruti ChaturvediBaltimore$265K
- Sandy KotiahBaltimore$247K
- Bruce SmithBaltimore$235K
- Evan LipsonBaltimore$228K
- Nilofer AzadBaltimore$143K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.